Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure (ADRIFT)

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study

Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure. The patients will be assessed at 10 and 90 days: central laboratory hemostasis analysis and clinical events assessment.

Study Overview

• Status: Completed
• Conditions: Hemorrhage; Atrial Fibrillation; Atrial Appendage
• Intervention / Treatment: Drug: Rivaroxaban 10 mg qd; Drug: Rivaroxaban 15 mg qd; Drug: DAPT

Detailed Description

Data on antithrombotic therapy after Left Atrial Appendage Closure (LAAC) are scarce and no randomized evaluation has been performed to demonstrate what is the best antithrombotic strategy following LAAC. LAAC is classically associated with a 6-week period of anticoagulation with warfarin + aspirin followed by once daily clopidogrel (75 mg) + aspirin (81-325 mg) until the 6 months visit, then aspirin alone is continued indefinitely, as tested in patients without contraindication for anticoagulation in the pivotal Watchman trials. LAAC is mostly used in Europe as an alternative to warfarin anticoagulation when patients have a contraindication to or are unsuitable for warfarin anticoagulation. The classic regimen is not applicable and believed to be too risky in such frail patients. These patients usually receive a regimen of daily clopidogrel + aspirin followed by single antiplatelet therapy (most frequently used treatment). Some patients receive oral anticoagulation without aspirin, including NOAC anticoagulation. Rivaroxaban is a tempting strategy for anticoagulation following LAAC in atrial fibrillation (AF) patients. The dose needs first to be carefully evaluated the trial propose a dose ranging study in patients who have undergone successful LAAC.

The study will evaluate two different Rivaroxaban regimen (10 or 15 mg a day) in comparison to dual antiplatelet therapy (DAPT) (aspirin+clopidogrel : control arm representing standard of care) after successful LAAC. The aim is to investigate whether rivaroxaban could provide correct anticoagulation levels and adequately suppress coagulation activation after LAAC.

The patient will be enrolled after left atrial appendage closure before discharge. The randomization is 1/1/1 between the 3 groups : rivaroxaban 10mg a day, rivaroxaban 15 mg a day and aspirin 75mg + clopidogrel 75 mg a day. At 10 and 90 days, the patients will be sampled for biological assessment : Prothrombin fragments 1+2, Factor Xa inhibitory activity, Russel Viper venom enzyme assay, thrombin anti-thrombin (TAT) complex, D-Dimers, Prothrombin time (Neoplastin) and plasma von Willebrand factor (vWf) Ag level

After 90 days, the patient will end his/her participation in the trial. Clinical endpoints (death, MI, Stroke, TIA, systemic embolism, extracranial major bleeding or clinically relevant non major bleeding) at 90 days will be assessed by a clinical endpoint committee. Central echographic laboratory will review all 90 days transesophageal echocardiography (TEE) to detect the presence of thrombus or peri-device leak.

The study is open-label. Central laboratory, clinical endpoint committee and echographic core laboratory is blinded to randomization arm.

• Study Type: Interventional
• Enrollment (Actual): 105
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• France
  • Paris, France, 75013
    • Institut de Cardiologie - Hôpital Pitié-Salpêtrière

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men and women ≥18 years of age
• Patients who underwent a clinically successful LAAC procedure (device implanted without procedural or bleeding complication). LAAC may have been indicated for patients contraindicated or unsuitable for long-term Vitamin K antagonists (VKA) anticoagulation.
• AF (permanent or persistent or paroxysmal) patients irrespective of prior antithrombotic treatment are eligible for randomization.
• Written informed consent by the patient or designee if the patient is unable to consent
• Patients affiliated to the French social security system

Exclusion Criteria:

• Creatinine clearance <30 mL / min (Cockcroft formula).
• Dialysis.
• Mechanical heart valves or valvular disease requiring surgery or interventional procedure
• Planned Ablation of AF during follow up period
• Mandatory indication for dual antiplatelet therapy (e.g. recent stent) or single anti-platelet treatment (SAPT) (e.g. high coronary risk).
• Any contra-indication or known allergy to aspirin or clopidogrel or rivaroxaban.
• Any mandatory indication for anticoagulation for a reason other than AF (e.g. Pulmonary embolism)
• Ongoing major bleeding or complicated or recent (<72hours) major surgery
• Known large oesophageal varices or decompensated liver disease (unless a documented positive opinion of a gastro-enterologist)
• Severe thrombocytopenia (<50,000/ml) after referral to haematologist to confirm or not contraindication
• Recent myocardial infarction (<6 weeks).
• Recent cerebro-vascular event (CVE) or transient ischemic attack (<6 weeks) after evaluation of stroke vs bleeding risk by the referring neurologist.
• Recent Intracranial bleeding (< 6 months): these patients will be evaluated by a neurologist as these patients may be considered at higher stroke risk. Neurologist may consider that the LAAC procedure with a short (90 days) period of anticoagulation or antiplatelet therapy as tested in the protocol is a preferable option (in that case intracranial hemorrhage (ICH) will not be considered as a contraindication).
• Prasugrel or ticagrelor concomitant use
• Participating in an investigational drug or another device trial within the previous 30 days.
• High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical.
• Woman with child bearing potential who do not use an efficient method of contraception.
• positive serum or urine pregnancy test for woman with child bearing potential
• Pregnancy or within 48 hours post-partum or breast feeding women
• Patient under legal protection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 1: Rivaroxaban 10 mg qd; Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM	Drug: Rivaroxaban 10 mg qd; 10mg qd; Other Names: Experimental
EXPERIMENTAL: 2: Rivaroxaban 15 mg qd; Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM	Drug: Rivaroxaban 15 mg qd; 15mg qd; Other Names: Experimental
ACTIVE_COMPARATOR: 3: DAPT; Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM	Drug: DAPT; Aspirin 75 mg qd + Clopidogrel 75 mg qd; Other Names: Active comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure of prothrombin fragment 1 + 2	Measure of prothrombin fragment 1 + 2 at Day 10 (2 to 4 hours after last intake : concentration peak)	at Day 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure of prothrombin fragment 1 + 2	Measure of prothrombin fragment 1 + 2 at Day 90 (2 to 4 hours after last intake : concentration peak)	at Day 90
Factor Xa inhibitory activity at day 10	Factor Xa inhibitory activity	at Day 10
Factor Xa inhibitory activity at day 90	Factor Xa inhibitory activity	at Day 90
Russel Viper venom enzyme assay	Russel Viper venom enzyme assay	at Day 90
TAT complex	TAT complex	at Day 10
TAT complex	TAT complex	at Day 90
D-Dimers	D-Dimersand at peak, 2 to 4 hours after treatment intake	at Day 10
D-Dimers	D-Dimersand at peak, 2 to 4 hours after treatment intake	at Day 90
Prothrombin time (Neoplastin)	Prothrombin time (Neoplastin)	at Day 10
Prothrombin time (Neoplastin)	Prothrombin time (Neoplastin)	at Day 90
Plasma vWf Ag level	plasma vWf Ag level treatment intake	at Day 10
Plasma vWf Ag level	plasma vWf Ag level treatment intake	at Day 90
Haemorrhagic stroke and bleeding will be safety outcomes TEE with central core lab reading: presence of thrombus, peri-device leak	Haemorrhagic stroke and bleeding will be safety outcomes 3-month TEE with central core lab reading: presence of thrombus, peri-device leak	at Day 90
Composite clinical endpoint combining all clinical outcomes	Composite clinical endpoint combining all clinical outcomes : Death, MI, stroke, TIA,	at Day 90
Death (any cause)	Death (any cause) assessed individually and combined at other outcomes	at Day 90
Myocardial infarction (MI)	Myocardial infarction (MI) assessed individually and combined at other outcomes	at Day 90
Stroke (ischaemic stroke, haemorrhagic stroke)	Stroke (ischaemic stroke, haemorrhagic stroke) assessed individually and combined at other outcomes	at Day 90
Transient Ischemic Attack (TIA)	Transient Ischemic Attack (TIA) assessed individually and combined at other outcomes	at Day 90
Systemic embolism	Systemic embolism assessed individually and combined at other outcomes	at Day 90
Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) at day 90	Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) assessed individually and combined at other outcomes	at Day 90

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: Bayer; Action Research Group
• Investigators: Principal Investigator: Gilles MONTALESCOT, MD, PhD, Centre Hospitalier Universitaire Pitié-Salpêtrière Paris

Publications and helpful links

General Publications

• Duthoit G, Silvain J, Marijon E, Ducrocq G, Lepillier A, Frere C, Dimby SF, Popovic B, Lellouche N, Martin-Toutain I, Spaulding C, Brochet E, Attias D, Mansourati J, Lorgis L, Klug D, Zannad N, Hauguel-Moreau M, Braik N, Deltour S, Ceccaldi A, Wang H, Hammoudi N, Brugier D, Vicaut E, Juliard JM, Montalescot G. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study. Circ Cardiovasc Interv. 2020 Jul;13(7):e008481. doi: 10.1161/CIRCINTERVENTIONS.119.008481. Epub 2020 Jul 17.

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 13, 2017
• Primary Completion (ACTUAL): November 20, 2018
• Study Completion (ACTUAL): September 30, 2019

Study Registration Dates

• First Submitted: August 11, 2017
• First Submitted That Met QC Criteria: September 4, 2017
• First Posted (ACTUAL): September 6, 2017

Study Record Updates

• Last Update Posted (ACTUAL): December 21, 2021
• Last Update Submitted That Met QC Criteria: December 20, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: Rivaroxaban; Anticoagulation; Dual antiplatelet therapy; Stroke prevention; Left atrial appendage closure
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Atrial Fibrillation; Hemorrhage; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protease Inhibitors; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Anticoagulants; Rivaroxaban
• Other Study ID Numbers: P161102J

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No